Adocia S.A.
ADOCY - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$170.44M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $170.44 Million |
|---|---|
| Enterprise Value | $189.98 Million |
| Earnings per Share | $-0.81 |
| Beta | 0.86 |
| Outstanding Shares | 19,807,000 |
Return
| Return on Equity | 571.06% |
|---|---|
| Return on Assets | -60.02% |
| Return on Invested Capital | -68.65% |
Valuation & Multiples
| P/E Ratio | -2.96 |
|---|---|
| PEG | -481.94 |
| Price to Sales | - |
| Price to Book Ratio | -11.8 |
| Enterprise Value to Revenue | 20.35 |
| Enterprise Value to EBIT | -14.63 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.23 |
| Debt to Equity | -9.9 |
Revenue Sources
No data
Last Earnings Call
Report Date
September 24, 2026
EPS Estimate
$-0.50
Consensus analyst estimateRevenue Estimate
$48,897
Consensus analyst estimateNext Earnings Call
Expected Date
March 3, 2027
EPS Estimate
$-0.53
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Adocia S.A.
80 employees
CEO: Olivier Soula
Adocia S.A. is a clinical-stage biotechnology firm that specializes in developing enhanced formulations of existing therapeutic proteins and peptides, primarily targeting diabetes and other metabolic disorders. The company leverages its ...